Clinical trials in metastatic uveal melanoma: Immunotherapy

M Orloff - Ocular Oncology and Pathology, 2021 - karger.com
Background: Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …
被引用次数：16 相关文章

Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy

M Orloff - Ocular Oncology and Pathology, 2021 - karger.com
Background: Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …

Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.

M Orloff - Ocular Oncology & Pathology, 2021 - search.ebscohost.com
Background: Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …

Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy

M Orloff - Ocular oncology and pathology, 2021 - pubmed.ncbi.nlm.nih.gov
Background Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …
[HTML] nih.gov

[HTML][HTML] Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy

M Orloff - Ocular Oncology and Pathology, 2021 - ncbi.nlm.nih.gov
Background Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …
[PDF] archive.org

[PDF][PDF] Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy

M Orloff - 2021 - scholar.archive.org
Background: Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …

Clinical Trials in Metastatic Uveal Melanoma: Immunotherapy.

M Orloff - Ocular Oncology and Pathology, 2021 - europepmc.org
Background Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor
prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors …